4 August 2017 - Cost regulators for NHS therapies in England and Wales have turned down MSD’s immunotherapy Keytruda as a treatment for locally advanced or metastatic urothelial cancer.

The National Institute for Health and Care Excellence has published an appraisal consultation document rejecting the drug for use in adults who have had prior platinum-containing chemotherapy.

The Committee noted that clinical trial evidence shows that Keytruda (pembrolizumab) significantly improves overall survival versus docetaxel and paclitaxel, the current treatment options patients, and that the drug is likely to extend survival by around three months.

Read Pharma Times article